uniQure (NASDAQ:QURE) Stock Rating Lowered by Wells Fargo & Company

uniQure (NASDAQ:QURE) was downgraded by equities research analysts at Wells Fargo & Company from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Several other research analysts have also recently issued reports on QURE. Wall Street Zen cut shares of uniQure from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Wolfe Research assumed coverage on shares of uniQure in a research report on Monday, February 23rd. They set a “peer perform” rating for the company. Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a research report on Tuesday. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research note on Tuesday. Finally, The Goldman Sachs Group dropped their target price on shares of uniQure from $37.00 to $9.00 and set a “neutral” rating for the company in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $34.33.

uniQure Stock Down 14.0%

Shares of NASDAQ:QURE opened at $9.03 on Monday. The stock has a market capitalization of $562.48 million, a P/E ratio of -2.62 and a beta of 0.73. The stock’s 50-day moving average price is $22.86 and its 200-day moving average price is $29.72. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23. uniQure has a 12-month low of $7.76 and a 12-month high of $71.50.

uniQure (NASDAQ:QURE) last issued its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.93) by $0.37. uniQure had a negative return on equity of 230.98% and a negative net margin of 1,236.00%.The company had revenue of $5.57 million during the quarter, compared to analysts’ expectations of $4.84 million. On average, equities analysts anticipate that uniQure will post -3.75 earnings per share for the current year.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 12,378 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total value of $295,339.08. Following the completion of the sale, the chief executive officer directly owned 639,076 shares in the company, valued at $15,248,353.36. This trade represents a 1.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the sale, the director directly owned 32,342 shares in the company, valued at approximately $796,260.04. The trade was a 44.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 50,598 shares of company stock worth $1,248,588. 4.79% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in QURE. Swiss National Bank bought a new stake in shares of uniQure during the 2nd quarter valued at $1,080,000. Sanders Morris Harris LLC bought a new position in shares of uniQure in the 3rd quarter worth about $5,081,000. Aberdeen Group plc lifted its position in uniQure by 6.9% during the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock valued at $171,593,000 after acquiring an additional 189,029 shares during the period. JPMorgan Chase & Co. boosted its stake in uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after acquiring an additional 1,491,486 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in uniQure in the second quarter worth about $872,000. Institutional investors own 78.83% of the company’s stock.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Q4 results beat the EPS consensus (reported loss narrower than expected) and revenue slightly exceeded estimates — provides near‑term financial relief but did not offset regulatory concerns. Q4 press release
• Positive Sentiment: Some analysts remain constructive after repricing: Chardan retained a “buy” rating (lowered PT) and Wells Fargo kept an “equal weight” stance, which could support buyer interest if worries ease. Analyst notes
• Neutral Sentiment: uniQure says it held a Type A meeting with the FDA, is evaluating Phase‑III plans for AMT‑130 and intends to request a follow‑up Type B meeting in Q2 — this signals a defined regulatory path but will likely take time and resources. Company update
• Neutral Sentiment: Corporate disclosure flagged a governance risk tied to a 2026 shift to the Dutch “large company” regime — a longer‑term structural governance change that bears monitoring but is not an immediate earnings driver. TipRanks note
• Negative Sentiment: Regulatory blow: the FDA told uniQure its early‑stage AMT‑130 data are insufficient for a marketing application and has recommended a randomized, sham‑controlled Phase III study — a materially more onerous and time‑consuming path that triggered the sharp market selloff. Reuters: FDA tells UniQure
• Negative Sentiment: Analysts slashed price targets and ratings after the FDA decision (Goldman lowered its PT to $9 and moved to neutral; Cantor, RBC, Mizuho and others also cut PTs or ratings) — analyst repricing removes supporting buy‑side momentum and amplifies downside risk. Analyst coverage changes
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs for securities class actions tied to the company’s disclosures during a defined class period — increased legal risk, potential settlements or litigation costs add uncertainty for shareholders. Rosen Law Firm notice
• Negative Sentiment: Market reaction: heavy volume and steep price declines since the FDA announcement reflect rapid repricing of AMT‑130’s value and higher execution risk for the company’s lead gene‑therapy program. Bloomberg coverage

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.